Estrogen-related receptor gamma functions as a tumor suppressor in gastric cancer

Myoung Hee Kang, Hyunji Choi, Masanobu Oshima, Jae Ho Cheong, Seokho Kim, Jung Hoon Lee, Young Soo Park, Hueng Sik Choi, Mi Na Kweon, Chan Gi Pack, Ju Seog Lee, Gordon Mills, Seung Jae Myung, Yun Yong Park

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The principle factors underlying gastric cancer (GC) development and outcomes are not well characterized resulting in a paucity of validated therapeutic targets. To identify potential molecular targets, we analyze gene expression data from GC patients and identify the nuclear receptor ESRRG as a candidate tumor suppressor. ESRRG expression is decreased in GC and is a predictor of a poor clinical outcome. Importantly, ESRRG suppresses GC cell growth and tumorigenesis. Gene expression profiling suggests that ESRRG antagonizes Wnt signaling via the suppression of TCF4/LEF1 binding to the CCND1 promoter. Indeed, ESRRG levels are found to be inversely correlated with Wnt signaling-associated genes in GC patients. Strikingly, the ESRRG agonist DY131 suppresses cancer growth and represses the expression of Wnt signaling genes. Our present findings thus demonstrate that ESRRG functions as a negative regulator of the Wnt signaling pathway in GC and is a potential therapeutic target for this cancer.

Original languageEnglish (US)
Article number1920
JournalNature Communications
Volume9
Issue number1
DOIs
StatePublished - Dec 1 2018
Externally publishedYes

Fingerprint

gamma function
estrogens
suppressors
Stomach Neoplasms
Tumors
Estrogens
tumors
cancer
Gene expression
Neoplasms
Genes
gene expression
Cell growth
Cytoplasmic and Nuclear Receptors
genes
Wnt Signaling Pathway
Gene Expression Profiling
Growth
estrogen receptor gamma
regulators

ASJC Scopus subject areas

  • Chemistry(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Physics and Astronomy(all)

Cite this

Kang, M. H., Choi, H., Oshima, M., Cheong, J. H., Kim, S., Lee, J. H., ... Park, Y. Y. (2018). Estrogen-related receptor gamma functions as a tumor suppressor in gastric cancer. Nature Communications, 9(1), [1920]. https://doi.org/10.1038/s41467-018-04244-2

Estrogen-related receptor gamma functions as a tumor suppressor in gastric cancer. / Kang, Myoung Hee; Choi, Hyunji; Oshima, Masanobu; Cheong, Jae Ho; Kim, Seokho; Lee, Jung Hoon; Park, Young Soo; Choi, Hueng Sik; Kweon, Mi Na; Pack, Chan Gi; Lee, Ju Seog; Mills, Gordon; Myung, Seung Jae; Park, Yun Yong.

In: Nature Communications, Vol. 9, No. 1, 1920, 01.12.2018.

Research output: Contribution to journalArticle

Kang, MH, Choi, H, Oshima, M, Cheong, JH, Kim, S, Lee, JH, Park, YS, Choi, HS, Kweon, MN, Pack, CG, Lee, JS, Mills, G, Myung, SJ & Park, YY 2018, 'Estrogen-related receptor gamma functions as a tumor suppressor in gastric cancer', Nature Communications, vol. 9, no. 1, 1920. https://doi.org/10.1038/s41467-018-04244-2
Kang, Myoung Hee ; Choi, Hyunji ; Oshima, Masanobu ; Cheong, Jae Ho ; Kim, Seokho ; Lee, Jung Hoon ; Park, Young Soo ; Choi, Hueng Sik ; Kweon, Mi Na ; Pack, Chan Gi ; Lee, Ju Seog ; Mills, Gordon ; Myung, Seung Jae ; Park, Yun Yong. / Estrogen-related receptor gamma functions as a tumor suppressor in gastric cancer. In: Nature Communications. 2018 ; Vol. 9, No. 1.
@article{1340c1b03c6d48c48ff639f291e8c7ab,
title = "Estrogen-related receptor gamma functions as a tumor suppressor in gastric cancer",
abstract = "The principle factors underlying gastric cancer (GC) development and outcomes are not well characterized resulting in a paucity of validated therapeutic targets. To identify potential molecular targets, we analyze gene expression data from GC patients and identify the nuclear receptor ESRRG as a candidate tumor suppressor. ESRRG expression is decreased in GC and is a predictor of a poor clinical outcome. Importantly, ESRRG suppresses GC cell growth and tumorigenesis. Gene expression profiling suggests that ESRRG antagonizes Wnt signaling via the suppression of TCF4/LEF1 binding to the CCND1 promoter. Indeed, ESRRG levels are found to be inversely correlated with Wnt signaling-associated genes in GC patients. Strikingly, the ESRRG agonist DY131 suppresses cancer growth and represses the expression of Wnt signaling genes. Our present findings thus demonstrate that ESRRG functions as a negative regulator of the Wnt signaling pathway in GC and is a potential therapeutic target for this cancer.",
author = "Kang, {Myoung Hee} and Hyunji Choi and Masanobu Oshima and Cheong, {Jae Ho} and Seokho Kim and Lee, {Jung Hoon} and Park, {Young Soo} and Choi, {Hueng Sik} and Kweon, {Mi Na} and Pack, {Chan Gi} and Lee, {Ju Seog} and Gordon Mills and Myung, {Seung Jae} and Park, {Yun Yong}",
year = "2018",
month = "12",
day = "1",
doi = "10.1038/s41467-018-04244-2",
language = "English (US)",
volume = "9",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Estrogen-related receptor gamma functions as a tumor suppressor in gastric cancer

AU - Kang, Myoung Hee

AU - Choi, Hyunji

AU - Oshima, Masanobu

AU - Cheong, Jae Ho

AU - Kim, Seokho

AU - Lee, Jung Hoon

AU - Park, Young Soo

AU - Choi, Hueng Sik

AU - Kweon, Mi Na

AU - Pack, Chan Gi

AU - Lee, Ju Seog

AU - Mills, Gordon

AU - Myung, Seung Jae

AU - Park, Yun Yong

PY - 2018/12/1

Y1 - 2018/12/1

N2 - The principle factors underlying gastric cancer (GC) development and outcomes are not well characterized resulting in a paucity of validated therapeutic targets. To identify potential molecular targets, we analyze gene expression data from GC patients and identify the nuclear receptor ESRRG as a candidate tumor suppressor. ESRRG expression is decreased in GC and is a predictor of a poor clinical outcome. Importantly, ESRRG suppresses GC cell growth and tumorigenesis. Gene expression profiling suggests that ESRRG antagonizes Wnt signaling via the suppression of TCF4/LEF1 binding to the CCND1 promoter. Indeed, ESRRG levels are found to be inversely correlated with Wnt signaling-associated genes in GC patients. Strikingly, the ESRRG agonist DY131 suppresses cancer growth and represses the expression of Wnt signaling genes. Our present findings thus demonstrate that ESRRG functions as a negative regulator of the Wnt signaling pathway in GC and is a potential therapeutic target for this cancer.

AB - The principle factors underlying gastric cancer (GC) development and outcomes are not well characterized resulting in a paucity of validated therapeutic targets. To identify potential molecular targets, we analyze gene expression data from GC patients and identify the nuclear receptor ESRRG as a candidate tumor suppressor. ESRRG expression is decreased in GC and is a predictor of a poor clinical outcome. Importantly, ESRRG suppresses GC cell growth and tumorigenesis. Gene expression profiling suggests that ESRRG antagonizes Wnt signaling via the suppression of TCF4/LEF1 binding to the CCND1 promoter. Indeed, ESRRG levels are found to be inversely correlated with Wnt signaling-associated genes in GC patients. Strikingly, the ESRRG agonist DY131 suppresses cancer growth and represses the expression of Wnt signaling genes. Our present findings thus demonstrate that ESRRG functions as a negative regulator of the Wnt signaling pathway in GC and is a potential therapeutic target for this cancer.

UR - http://www.scopus.com/inward/record.url?scp=85047217979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047217979&partnerID=8YFLogxK

U2 - 10.1038/s41467-018-04244-2

DO - 10.1038/s41467-018-04244-2

M3 - Article

VL - 9

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

IS - 1

M1 - 1920

ER -